Impact Biomedical

General Information

Impact Biomedical Inc. (“IBIO”) is a subsidiary of DSS, Inc (“DSS”: NYSE). IBIO discovers, confirms, and patents unique science and technologies that can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures and other relationships. (Incorporated in Nevada)

Our activities range from discovering technologies and leveraging those technologies to creating and commercializing product candidates. Currently, our operations are conducted, and our assets are owned primarily through our principal subsidiaries: Global BioLife, Inc., incorporated on April 14, 2017; Impact BioLife Science, incorporated on August 28, 2020; Global BioMedical, Inc., incorporated on April 18, 2017, and Sweet Sense, Inc., incorporated on April 30, 2018.

Through our majority-owned subsidiary Global BioLife, we own or have rights to a portfolio of biomedical intellectual property, including intellectual property assigned to Global BioLife by GRDG Sciences, LLC (“GRDG”). Global BioLife leverages its scientific know-how and intellectual property rights to develop various emerging technologies, including biopharmaceuticals, antivirals, antimicrobials, sugar alternatives, insect repellents, fragrances, bioplastics and natural preservatives.

Products under development include Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Polyphenols are substances found in many nuts, vegetables and berries. Linebacker compounds are modified Myricetin, which is a common plant-derived flavonoid. Myricetin exhibits a wide range of activities that include strong anti-oxidant, as well as potential anti-cancer, anti-inflammatory activities (source: NIH). Linebacker can potentially be developed as monotherapy or co-therapy to down-regulate PIM (proviral integration site for Moloney murine leukemia virus) kinase which plays a key role as an oncogene in various cancers (e.g. colon, lung, prostate, breast). Additional potential applications include inflammatory disorders and neurology. Lineebacker-1 and Linebacker-2 compounds have been licensed to ProPhase Laboratories for development and commercialization worldwide. Composition and method patents are issued for Linebacker in the U.S. and other countries.

Note: Two compounds from the Linebacker platform (LB-1, LB-2) are licensed to ProPhase Laboratories (PRPH: NASDAQ) for clinical development and commercialization for which Impact Biomedical could receive future milestone payments and royalties.

Other products and technology under development include:

  • Laetose – Laetose technology is derived from a unique combination of sugar and inositol, which has the potential ability to inhibit the inflammatory and metabolic response of sugar alone. Use of Laetose in a daily diet, compared to sugar, could result in 30% lower sugar consumption and lower caloric and glycemic index/load. Patents/Intellectual Property Summary Laetose U.S. composition and method patent is filed, published, and awaiting issue. We are actively seeking potential partners for further development and commercialization of Laetose as a consumer packaged offering worldwide.

  • Functional Fragrance Formulation (“3F”) – 3F is a suite of “functional fragrances” containing specialized botanical ingredients (e.g., terpenes) with potential application as an antimicrobial, or as an additive in insect repellents, detergents, lotions, shampoo, fabrics and other substances to increase effectiveness. We are actively seeking potential partners for further development and commercialization of 3F.


*Note: Net loss is for the 12 months that ended March 31, 2024.

(Note: Impact Biomedical, Inc. cut the size of its IPO in half – to 1.5 million shares – down from 3.0 million shares and kept the price range at $3.00 to $5.00 to raise $6.0 million, in an S-1/A filing dated June 11, 2024. In that same S-1/A filing, Impact Biomedical named Revere Securities as its sole book-runner to replace Aegis Corp. Background: Impact Biomedical, Inc. disclosed its proposed stock symbol – “IBO” – in its S-1/A filing dated Nov. 21, 2023. Impact Biomedical, Inc. filed an S-1/A dated Nov. 1, 2023, in which it disclosed the terms for its IPO: 2.0 million shares at $3.00 to $5.00 to raise $8.0 million. The proposed stock symbol  has not been disclosed. The prospectus says that a 1-to-55 ratio reverse stock split will take place. Background: Impact Biomedical, Inc. filed its S-1 on Oct. 17, 2023, without disclosing terms for its IPO.)

Industry: Pharmaceuticals - Drug R&D
Founded: 2017
Contact Information
Address 1400 Broadfield Blvd., Suite 130 Houston, TX 77084
Phone Number (585) 325-3610
Web Address
View Prospectus: Impact Biomedical
Financial Information
Market Cap $46.0mil
Revenues $0 mil (last 12 months)
Net Income $-4.56 mil (last 12 months)
IPO Profile
Symbol IBO
Exchange NYSE - American
Shares (millions): 1.5
Price range $3.00 - $5.00
Est. $ Volume $6.0 mil
Manager / Joint Managers Revere Securities
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change